Augmentation of Dopaminergic Agents for Major Depressive Disorder
J Clin Psychiatry 2009;70(3):432-433 [letter]
© Copyright 2015 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Letter to the Editor
Sir: We read with great interest the randomized,
double-blind, placebo-controlled clinical trial (RCT) entitled
“Osmotic-Release Oral System Methylphenidate Augmentation
of Antidepressant Monotherapy in Major Depressive Disorder:
Results of a Double-Blind, Randomized, Placebo-Controlled
Trial” (osmotic-release oral system methylphenidate [OROS
MPH] N = 73, placebo N = 72; mean dose of OROS MPH =
36.4 mg/day), which followed our earlier 4-week RCT (OROS
MPH N = 30, placebo N = 30; mean dose of OROS MPH =
34.2 mg/day). In their article, Ravindran et al. referenced our
study only in the form of an abstract that was presented in a scientific
meeting, without providing any detailed comparisons between
the 2 studies. We therefore will briefly introduce our
study results using a meta-analytic approach to extract findings
from the 2 studies in order to achieve better sample power. We
also provide meta-analytic findings from 4 RCTs of modafinil
augmentation for unipolar and bipolar depression.